Get the Stockscreener App
45.79
0.00%
0.0028
Royalty Pharma Plc stock is traded at $45.79, with a volume of 152.13K.
It is up +0.00% in the last 24 hours and up +1.51% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$45.79
Open:
$45.78
24h Volume:
152.13K
Relative Volume:
0.04
Market Cap:
$19.62B
Revenue:
$2.38B
Net Income/Loss:
$1.32B
P/E Ratio:
25.71
EPS:
1.7806
Net Cash Flow:
$897.24M
1W Performance:
-0.17%
1M Performance:
+1.51%
6M Performance:
+26.35%
1Y Performance:
+37.05%
1-Day Range:
$45.66
$45.97
1-Week Range:
$45.31
$46.44
52-Week Range:
$29.66
$47.86
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.79 | 19.62B | 2.38B | 1.32B | 897.24M | 1.7806 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.60 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.21 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
685.06 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.65 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.62 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma plc (RPRX) earns $51 target as 2026 growth outlook exceeds expectations - MSN
[144] Royalty Pharma plc SEC Filing - Stock Titan
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
54,266 Shares in Royalty Pharma PLC $RPRX Acquired by WBI Investments LLC - MarketBeat
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout - ChartMill
Royalty Pharma names Greg Butz as EVP of partnering, investments By Investing.com - Investing.com South Africa
Royalty Pharma Announces Expansion of Leadership Team - The Manila Times
Royalty Pharma hires Bank of America healthcare banking executive - StreetInsider
Royalty Pharma PLC $RPRX Shares Bought by L2 Asset Management LLC - MarketBeat
Royalty Pharma Plc Experiences Valuation Adjustment Amid Strong Market Performance Metrics - Markets Mojo
Dorsey Asset Management LLC Buys Shares of 2,350,449 Royalty Pharma PLC $RPRX - MarketBeat
Clark Capital Management Group Inc. Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
182,068 Shares in Royalty Pharma PLC $RPRX Acquired by Braidwell LP - MarketBeat
Swiss National Bank Sells 22,000 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : TD Cowen Conference Transcript - marketscreener.com
Royalty Pharma Plc Experiences Valuation Adjustment Amidst Competitive Market Dynamics - Markets Mojo
Royalty Pharma PLC $RPRX Shares Bought by Korea Investment CORP - MarketBeat
A Look At Royalty Pharma (RPRX) Valuation After New Asia Expansion Leadership Appointment - Sahm
Magnetar Financial LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
The Bull Case For Royalty Pharma (RPRX) Could Change Following Asia Leadership Hire To Target Biotech Royalties - simplywall.st
WINTON GROUP Ltd Takes $3.36 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Capital International Investors Raises Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Capital International Sarl - MarketBeat
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 10th Largest Position - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Decreased by Rhenman & Partners Asset Management AB - MarketBeat
Neo Ivy Capital Management Buys New Position in Royalty Pharma PLC $RPRX - MarketBeat
Goodman Advisory Group LLC Purchases New Stake in Royalty Pharma PLC $RPRX - MarketBeat
CM Management LLC Takes $1.76 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma - MSN
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Royalty Pharma Plc Hits New 52-Week High of USD 47.86 - Markets Mojo
Vera Therapeutics Appoints Christopher Hite to Board of Directors - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.66 - Markets Mojo
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Insider sales of common stock — Repare Therapeutics (NASDAQ: RPRX) - Stock Titan
Victory Capital Management Inc. Purchases 165,727 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Earnings History & Surprises | EPS & Revenue Results | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Royalty Pharma at TD Cowen Conference: Strategic Growth Insights - Investing.com Nigeria
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations - Yahoo Finance
RPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Royalty Pharma (RPRX) Passes Through 2% Yield Mark - Nasdaq
Royalty Pharma Plc Hits New 52-Week High of USD 46.37 - Markets Mojo
TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz
Royalty Pharma appoints Kenneth Sun to lead Asia expansion By Investing.com - Investing.com Australia
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Mar 02 '26 |
Sale |
46.78 |
34,791 |
1,627,534 |
45,761 |
0.65%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):